Pre-exposure prophylaxis and its implications in Mexico: notions of men who have sex with men
R. Baruch A , S. M. Cuadra B E , J. Arellano C , D. Sánchez D , D. V. Ortega B and A. Arredondo B
+ Author Affiliations
- Author Affiliations
A Escuela de Salud Pública de México, Instituto Nacional de Salud Pública, Avenida Universidad 655, Colonia Santa María Ahuacatitlán, Cuernavaca, Morelos, CP 62100, México.
B Centro de Investigación en Sistemas de Salud, Instituto Nacional de Salud Pública de México, Instituto Nacional de Salud Pública, Avenida Universidad 655, Colonia Santa María Ahuacatitlán, Cuernavaca, Morelos, CP 62100, México.
C Programa Conjunto de las Naciones Unidas sobre el VIH/Sida, Coordinación en México, Homero 806, colonia Polanco IV sección, Delegación Benito Juárez, Ciudad de México 11550, México.
D Dirección General para la Organización de las Naciones Unidas, Secretaría de Relaciones Exteriores, Avenida Juárez, Centro, Ciudad de México 06000, México.
E Corresponding author. Email: magali.cuadra@insp.mx
Sexual Health 17(1) 22-28 https://doi.org/10.1071/SH18193
Submitted: 1 April 2018 Accepted: 2 July 2019 Published: 23 January 2020
Abstract
Background: The aim of this study was to analyse ideas regarding pre-exposure prophylaxis (PrEP) for the prevention of HIV among groups of men who have sex with men in Mexico for future implementation in health services. Methods: During 2015, 54 people participated in four focus groups in three Mexican cities. Issues related to challenges for uses and limitations of PrEP were explored. Results: In contrast with other qualitative studies, which emphasised problems with relationships with other people for PrEP use or access to key populations, Mexican participants focused their concerns around the public health services organisation: PrEP is too expensive and the health services have no resources, which will affect services and result in discrimination. Participants identified possible stigmatisation related to prejudices of medical providers who do not approve the decreased use of condoms. As a potential solution, participants suggested that the Mexican Government could negotiate a lower cost for PrEP and public health services could provide the medication, with periodical review of the arrangements by civil organisations. Conclusion: In the current context of the new Mexican government, it is necessary to propose public politics focused on negotiating with pharmaceutical companies on the costs of the PrEP, coordinating public services with groups within civil society and strengthening policies and actions to reduce stigma and discrimination.
Additional keywords: HIV prevention, qualitative research, stigmatisation.
References
[1] Joint United Nations Programme on HIV/AIDS (UNAIDS). Global Report: UNAIDS report in the global AIDS epidemic. Geneva: UNAIDS; 2013.[2] Bautista S, Colchero A, Romero M, Conde C, Sosa S. Is the HIV epidemic stable among MSM in Mexico? HIV prevalence and risk behavior results from a nationally representative survey among men who have sex with men. PLoS ONE 2013; 8 e72616
| Is the HIV epidemic stable among MSM in Mexico? HIV prevalence and risk behavior results from a nationally representative survey among men who have sex with men.Crossref | GoogleScholarGoogle Scholar |
[3] Gutiérrez JP, Sucilla-Pérez H, Conde-González CJ, Izazola JA, Romero-Martínez M, Hernández-Ávila M. Seroprevalencia de VIH en población Mexicana de 15 a 49 años: resultados de ENSANUT 2012. Salud Publica Mex 2014; 56 323–32.
| Seroprevalencia de VIH en población Mexicana de 15 a 49 años: resultados de ENSANUT 2012.Crossref | GoogleScholarGoogle Scholar | 25604172PubMed |
[4] Vigilancia Epidemiológica de casos de VIH/SIDA en México (Censida). Registro Nacional de Casos de SIDA. Actualización al Cierre de 2017. Censida/Secretaría de Salud; 2019. Available online at: https://www.gob.mx/cms/uploads/attachment/file/328393/RN_Cierre_2017.pdf [verified 31 October 2019].
[5] World Health Organization (WHO). WHO expands recommendation on oral pre-exposure prophylaxis of HIV infection (PrEP). [Policy Brief] Geneva: WHO; 2015. Available online at: https://www.who.int/hiv/pub/prep/policy-brief-prep-2015/en/ [verified 8 October 2019].
[6] World Health Organization (WHO). Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. Geneva: WHO; 2014.
[7] Joint United Nations Programme on HIV/AIDS (UNAIDS). Oral pre-exposure prophylaxis: putting a new choice in context. 2015. Available online at: http://www.unaids.org/sites/default/files/media_asset/UNAIDS_JC2764_en.pdf [verified 31 October 2019].
[8] Ayala G, Makofane K, Santos GM, Beck J, Do T, Herbert P, et al. Access to basic HIV-related services and PrEP acceptability among MSM worldwide: barriers, facilitators and implications for combination prevention. J Sex Transm Dis 2013; 2013 953123
| 26316968PubMed |
[9] Amico KR, Stirrat M. Adherence to preexposure prophylaxis: current, emerging and anticipated bases of evidence. Clin Infect Dis 2014; 59 S55–60.
| Adherence to preexposure prophylaxis: current, emerging and anticipated bases of evidence.Crossref | GoogleScholarGoogle Scholar | 24926036PubMed |
[10] Volk JE, Marcus JL, Phengrasamy T, Blechinger D, Nguyen DP, Follansbee S, et al. No new HIV infections with increased HIV pre-exposure prophylaxis in a clinical practice setting. Clin Infect Dis 2015; 61 1601–3.
| No new HIV infections with increased HIV pre-exposure prophylaxis in a clinical practice setting.Crossref | GoogleScholarGoogle Scholar | 26334052PubMed |
[11] Padian NS, McCoy SI, Abdool-Karim SS, Hasen N, Kim J, Bartos M, et al. HIV prevention transformed: the new prevention research agenda. Lancet 2011; 378 269–78.
| HIV prevention transformed: the new prevention research agenda.Crossref | GoogleScholarGoogle Scholar | 21763938PubMed |
[12] Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O’Reilly KR, Koechlin FM, et al. Effectiveness and safety of oral PrEP for all populations: a systematic review and meta-analysis. AIDS 2016; 30 1973–83.
| Effectiveness and safety of oral PrEP for all populations: a systematic review and meta-analysis.Crossref | GoogleScholarGoogle Scholar | 27149090PubMed |
[13] Baruch R. Resultados preliminares de ‘Encuesta de Sexo entre Hombres’: La Profilaxis Pre-Exposición al VIH: los retos para su implementación en México. Congress Communication, Día Mundial vs Homofobia, Octubre de 2015. México: Censida; 2017.
[14] Instituto Nacional de Estadística y Geografía. Encuesta Nacional de Ingresos y Gastos de los Hogares (ENIGH) 2016. 2016. Available online at: https://www.inegi.org.mx/contenidos/programas/enigh/nc/2016/doc/presentacion_resultados_enigh2016.pdf [verified 31 October 2019].
[15] López-Arellano O, Gil-Blanco J. La polarización de la política de salud en México. Cad Saude Publica 2001; 17 43–54.
| La polarización de la política de salud en México.Crossref | GoogleScholarGoogle Scholar | 11241926PubMed |
[16] Infante C, Zarco A, Cuadra-Hernández SM, Morrison K, Caballero M, Bronfman M, et al. El estigma asociado al VIH/SIDA: el caso de los prestadores de servicios de salud en México. Salud Publica Mex 2006; 48 141–50.
| El estigma asociado al VIH/SIDA: el caso de los prestadores de servicios de salud en México.Crossref | GoogleScholarGoogle Scholar | 16619870PubMed |
[17] Holt M, Lea T, Mao L, Kolstee J, Zablotska I, Duck T, et al. Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013–17. Lancet 2018; 5 e448–56.
| 29885813PubMed |
[18] Crosby RA. Dealing with pre-exposure prophylaxis-associated condom migration: changing the paradigm for men who have sex with men. Sex Health 2017; 14 106–10.
| Dealing with pre-exposure prophylaxis-associated condom migration: changing the paradigm for men who have sex with men.Crossref | GoogleScholarGoogle Scholar | 27585107PubMed |
[19] 19 PrEP Watch. Global PrEP tracker. 2019. Available online at: https://www.prepwatch.org/resource/global-prep-tracker/ [verified 31 October 2019].
[20] Diario Oficial de la Federación. Norma Oficial Mexicana NOM-012-SSA3-2012, Que establece los criterios para la ejecución de proyectos de investigación para la salud en seres humanos. 2012. Available online at: http://dof.gob.mx/nota_detalle.php?codigo=5284148&fecha=04/01/2013 [verified 31 October 2019].
[21] Desmarais D, Grell P, comps. Les récits de vie: théorie, mèthode et trajectoires types. Montreal: Editions Saint-Martin; 1986.
[22] Braun B, Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006; 3 77–101.
| Using thematic analysis in psychology.Crossref | GoogleScholarGoogle Scholar |
[23] Cuadra SM, Baruch R, Infante C, Granados JA. ‘Dame una pastilla’: los significados del VIH/Sida en la práctica del bareback en México. Salud Publica Mex 2015; 57 S113–18.
[24] Elopre L, McDavid C, Brown A, Shurbaji S, Mugavero M, Turan J. Perceptions of HIV pre-exposure prophylaxis among young, black men who have sex with men. AIDS Patient Care STDS 2018; 32 511–18.
| Perceptions of HIV pre-exposure prophylaxis among young, black men who have sex with men.Crossref | GoogleScholarGoogle Scholar | 31021175PubMed |
[25] Grace D, Jollimore J, MacPherson P, Strang MJP, Tan DHS. The pre-exposure prophylaxis-stigma paradox: learning from Canada’s first wave of PrEP users. AIDS Patient Care STDS 2018; 32 24–30.
| The pre-exposure prophylaxis-stigma paradox: learning from Canada’s first wave of PrEP users.Crossref | GoogleScholarGoogle Scholar | 29185801PubMed |
[26] Jaspal R, Daramilas C. Perceptions of pre-exposure prophylaxis (PrEP) among HIV-negative and HIV-positive men who have sex with men (MSM). Cogent Med 2016; 3 1256850
[27] Ahouada C, Diabaté S, Gning N, Hessou S, Batona G, Guédou F, et al. Acceptability of pre-exposure prophylaxis (PrEP) among men who have sex with men (MSM) in Benin: a qualitative study. AIDS Care 2019.;
| Acceptability of pre-exposure prophylaxis (PrEP) among men who have sex with men (MSM) in Benin: a qualitative study.Crossref | GoogleScholarGoogle Scholar | 31129988PubMed |
[28] Varela-Arévalo MT, Hoyos-Hernández P. La adherencia al tratamiento para el VIH/SIDA: más allá de la toma de antirretrovirales. Rev Salud Publica (Bogota) 2015; 17 528–40.
| La adherencia al tratamiento para el VIH/SIDA: más allá de la toma de antirretrovirales.Crossref | GoogleScholarGoogle Scholar | 28453073PubMed |
[29] Grant R, Glidden D. HIV moments and pre-exposure prophylaxis. Lancet 2016; 387 1507–8.
| 27115970PubMed |
[30] Mutua G, Sanders E, Mugo P, Anzala O, Haberer JE, Bangsberg D, et al. Safety and adherence to intermittent PrEP for HIV-1 in African men who have sex with men and female sex workers. PLoS ONE 2012; 7 e33103
| Safety and adherence to intermittent PrEP for HIV-1 in African men who have sex with men and female sex workers.Crossref | GoogleScholarGoogle Scholar | 22558192PubMed |
[31] Wenger LD, Lopez AM, Comfort M, Kral AH. The phenomenon of low-frequency heroin injection among street-based urban poor: drug user strategies and contexts of use. Int J Drug Policy 2014; 25 471–9.
| The phenomenon of low-frequency heroin injection among street-based urban poor: drug user strategies and contexts of use.Crossref | GoogleScholarGoogle Scholar | 24690452PubMed |
[32] Cuadra-Hernández SM, Salazar-Arriola S, Arredondo-López A, Duarte-Gómez MB, Cuadra-Hernández V, Rueda-Neria C. Experiences and perceptions of people who use heroin: public health lessons from Hermosillo, Mexico. Cad Saude Publica 2018; 34 e00179417
| 30484562PubMed |
[33] Boucher LM, Marshall Z, Martin A, Larose-Hébert K, Flynn JV, Lalonde C, et al. Expanding conceptualizations of harm reduction: results from a qualitative community-based participatory research study with people who inject drugs. Harm Reduct J 2017; 14 18
| Expanding conceptualizations of harm reduction: results from a qualitative community-based participatory research study with people who inject drugs.Crossref | GoogleScholarGoogle Scholar | 28494774PubMed |
[34] Collins SP, McMahan VM, Stekler JD. The impact of HIV pre-exposure prophylaxis (PrEP) use on the sexual health of men who have sex with men: a qualitative study in Seattle, WA. Int J Sex Health 2017; 29 55–68.
| The impact of HIV pre-exposure prophylaxis (PrEP) use on the sexual health of men who have sex with men: a qualitative study in Seattle, WA.Crossref | GoogleScholarGoogle Scholar |
[35] Kurtz SP, Buttram ME. Misunderstanding of pre-exposure prophylaxis use among men who have sex with men: public health and policy implications. LGBT Health 2016; 3 461–4.
| Misunderstanding of pre-exposure prophylaxis use among men who have sex with men: public health and policy implications.Crossref | GoogleScholarGoogle Scholar | 26720130PubMed |
[36] Newman C, Hughes S, Persson A, Truong H, Holt M. Promoting ‘equitable access’ to PrEP in Australia: taking account of stakeholder perspectives. AIDS Behav 2019; 23 1846–57.
| Promoting ‘equitable access’ to PrEP in Australia: taking account of stakeholder perspectives.Crossref | GoogleScholarGoogle Scholar | 30306435PubMed |
[37] Wheelock A, Eisingerich AB, Gomez GB, Gray E, Dybul MR, Piot P. Views of policymakers, healthcare workers and NGOs on HIV pre-exposure prophylaxis (PrEP): a multinational qualitative study. BMJ Open 2012; 2 e001234
| Views of policymakers, healthcare workers and NGOs on HIV pre-exposure prophylaxis (PrEP): a multinational qualitative study.Crossref | GoogleScholarGoogle Scholar | 22761288PubMed |
[38] Ravasi G, Grinsztejn B, Baruch R, Guanira JV, Luque R, Cáceres CF, et al. Towards a fair consideration of PrEP as part of combination prevention in Latin America. J Int AIDS Soc 2016; 19 21113
| Towards a fair consideration of PrEP as part of combination prevention in Latin America.Crossref | GoogleScholarGoogle Scholar | 27760687PubMed |
[39] Hankins C, Macklin R, Warren M. Translating PrEP effectiveness into public health impact: key considerations for decision-makers on cost-effectiveness, price, regulatory issues, distributive justice and advocacy for access. J Int AIDS Soc 2015; 18 19973
| Translating PrEP effectiveness into public health impact: key considerations for decision-makers on cost-effectiveness, price, regulatory issues, distributive justice and advocacy for access.Crossref | GoogleScholarGoogle Scholar | 26198343PubMed |
[40] Ouellet E, Durand M, Guertin J, LeLourier J, Trembley C. Cost effectiveness of ‘on demand’ HIV PrEP for MSM in Canada. Can J Infect Dis Med Microbiol 2015; 26 23–9.
| Cost effectiveness of ‘on demand’ HIV PrEP for MSM in Canada.Crossref | GoogleScholarGoogle Scholar | 25798150PubMed |
[41] Ong KJ, Desai S, Desai M, Nardone A, Jan van Hoek A, Gill ON. Cost and cost-effectiveness of an HIV pre-exposure prophylaxis (PrEP) programme for high-risk men who have sex with men in England: results of a static decision analytical model. Lancet 2015; 386 S16
[42] Hernández M, González de Araujo A, Sánchez GH, Calva JJ, Chaumont C, Bautista S, et al. Marco legal, clínico y económico de la compra de antiretrovirales en México. Mexico City: CENSIDA/Ángulos del SIDA; 2015.
[43] Cáceres CF, O’Reilly KR, Mayer KH, Baggaley R. PrEP implementation: moving from trials to policy and practice. J Int AIDS Soc 2015; 18 20222
| PrEP implementation: moving from trials to policy and practice.Crossref | GoogleScholarGoogle Scholar | 26198349PubMed |
[44] Vega A. 327 denuncias por falta de medicina en instituciones públicas, registra plataforma ciudadana. 2019. Available online at: https://www.animalpolitico.com/2019/05/medicinas-desabasto-plataforma-ciudadana/ [verified 31 October 2019].
[45] Suárez K. El viacrucis de las personas con VIH y sida en México para recibir tratamiento. Los pacientes denuncian retrasos hasta de tres meses en el abasto de medicamentos. 2019. Available online at: https://elpais.com/sociedad/2019/05/31/actualidad/1559326083_488889.html [verified 31 October 2019].
[46] Cruz-Martínez A. Nueva subsecretaría de Ssa vigilará el uso de dinero para los estados. 2019. Available online at: https://www.jornada.com.mx/2019/06/11/sociedad/029n1soc# [verified 31 October 2019].
